Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
AssigneeSpring BioScience Corporation
InventorsFernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
Life of this patent
Estimating the term…
Abstract
The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), nucleic acids encoding the same, and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).
Claims21
A method of detecting the presence or expression level of indoleamine 2,3-dioxygenase 1 (IDO1) in a biological sample, the method comprising contacting the biological sample with an anti-IDO1 antibody and detecting the presence of the antibody bound to the biological sample, wherein the anti-IDO1 antibody comprises the following heavy chain hypervariable regions (HVR-H) and light chain hypervariable regions (HVR-L):
- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 2;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 3;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 4;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 9;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 10;
- and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 11.
An entity selected from the group consisting of:
- (a) an isolated peptide comprising SEQ ID NO:
- 1, wherein said isolated peptide has a length from 12 to 50 amino acids;
- and
- (b) a fusion protein comprising the isolated peptide of (a) linked to a carrier protein;
- (c) a rabbit, rat, mouse, or goat immunized with the isolated peptide of (a) of the fusion protein of (b);
- (d) an isolated B cell obtained from the rabbit, rat, mouse, or goat according to (c);
- and
- (e) a hybridoma produced from the isolated B cell according to (d).
An entity selected from the group consisting of:
- (a) an isolated nucleic acid encoding an antibody heavy chain having the following heavy chain hypervariable regions (HVR-H):
- (a1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 2;
- (a2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 3;
- (a3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 4;
- or
- (b) an isolated nucleic acid encoding an antibody light chain having the following light chain hypervariable regions (HVR-L):
- (b1) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 9;
- (b2) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 10;
- and
- (b3) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 11;
- (c) an isolated nucleic acid encoding an antibody having the following HVR-H and HVR-L:
- (a1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 2;
- (a2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 3;
- (a3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 4;
- or
- (b1) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 9;
- (b2) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 10;
- and
- (b3) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 11;
- (d) an expression vector comprising the isolated nucleic acid of (a), (b), or (c);
- and
- (e) a host cell comprising the expression vector of (d).
Dependencies are inferred from the claim text.